Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Tailoring prostate cancer radiotherapy to body clock could cut long-term side effects (opens in a new tab)

news-medical.net · 2026-10-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 4 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Four of seven check out. Two claims the study doesn't address.

  • 4 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedA study by Leicester researchers shows that the timing of radiotherapy treatment may be as important as how it is given for prostate cancer patients.View evidenceHide evidence

Why this verdict

The abstract supports that radiotherapy time-of-day, circadian genotypes, and their interaction are associated with late urinary incontinence and rectal bleeding risk. It does not establish that timing is 'as important as how it is given,' nor does it compare timing with radiotherapy technique or delivery method. As a headline, this outruns the paper evidence and the story’s more cautious body framing.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
Claim 2 of 7Not coveredThe findings, published in Clinical Cancer Research, suggest that a simple change to treatment scheduling, based on a patient's genetic profile, could help reduce complications such as urinary incontinence and rectal bleeding without diminishing the effectiveness of cancer treatment.View evidenceHide evidence

Why this verdict

The abstract supports the speculative idea that genotype-guided chronomodulation could reduce late side-effect risk for some patients, based on model-predicted risk differences. However, the supplied abstract-level profile does not report cancer-control or treatment-effectiveness outcomes, so the claim that scheduling could reduce complications 'without diminishing' cancer treatment effectiveness is not verifiable at this depth.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
2

Study evidence

Models including genotype, treatment timing, and their interaction predict that patients with PER3 rs696305 C/C (44% of cohort) would reduce predicted late rectal bleeding risk from 11% (treatment at 9:00 am) to 5% (treatment at 5:00 pm).11% → 5% absolute risk for RB

“Least absolute shrinkage and selection operator (LASSO) and logistic regression models incorporated genotypes of single-nucleotide polymorphisms in circadian rhythm genes, time of radiotherapy, and their interaction.”
Claim 3 of 7Not coveredThe researchers stress that further validation studies and clinical trials are needed before treatment schedules are routinely altered.View evidenceHide evidence

Why this verdict

The paper profile’s limitations support caution because the analysis is observational, model-based, complete-case, and lacks external validation details in the abstract. However, the supplied abstract-level profile does not specifically state that the researchers called for validation studies and clinical trials before routine schedule changes, so that attribution is not verifiable at this depth.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
2

Study evidence

Models including genotype, treatment timing, and their interaction predict that patients with PER3 rs696305 C/C (44% of cohort) would reduce predicted late rectal bleeding risk from 11% (treatment at 9:00 am) to 5% (treatment at 5:00 pm).11% → 5% absolute risk for RB

“Least absolute shrinkage and selection operator (LASSO) and logistic regression models incorporated genotypes of single-nucleotide polymorphisms in circadian rhythm genes, time of radiotherapy, and their interaction.”
Claim 4 of 7SupportedResearchers at the University of Leicester discovered that a patient's genetic makeup and the time of day they receive radiotherapy can work together to influence their risk of developing long-term side effects for treatment of prostate cancer.View evidenceHide evidence

Why this verdict

The abstract reports models including circadian SNP genotypes, radiotherapy time-of-day, and genotype×time interaction, with significant effects for late rectal bleeding and urinary incontinence. This supports the claim that genetic makeup and treatment time work together in relation to long-term side-effect risk, provided it is understood as observational association rather than proven causation.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
Claim 5 of 7SupportedThe article says the side effects are influenced by common genetic variations in PER3, a gene involved in regulating the body's circadian rhythm, and by the time of day at which radiotherapy is delivered.View evidenceHide evidence

Why this verdict

The paper profile states that PER3/circadian SNP genotypes, radiotherapy time-of-day, and their interaction were modeled and showed significant effects for late rectal bleeding and urinary incontinence. This supports the story’s body claim if 'influenced' is read as an association/model effect rather than causal proof.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
Claim 6 of 7SupportedUsing advanced statistical modeling on genetic information, radiotherapy treatment times, and two years of follow-up data, the team identified different PER3 genotype profiles with different side-effect risks at different times of day.View evidenceHide evidence

Why this verdict

The abstract-level profile reports use of genotype data, recorded radiotherapy fraction times, 2-year follow-up outcomes, LASSO variable selection, and logistic regression models. It also reports genotype-specific predicted risks at different treatment times, matching the story’s description.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
2

Study evidence

Models including genotype, treatment timing, and their interaction predict that patients with PER3 rs696305 C/C (44% of cohort) would reduce predicted late rectal bleeding risk from 11% (treatment at 9:00 am) to 5% (treatment at 5:00 pm).11% → 5% absolute risk for RB

“Least absolute shrinkage and selection operator (LASSO) and logistic regression models incorporated genotypes of single-nucleotide polymorphisms in circadian rhythm genes, time of radiotherapy, and their interaction.”
Claim 7 of 7SupportedThe researchers say some groups could reduce urinary incontinence risk from 15% to 5% by avoiding treatment around midday, while another side-effect estimate for rectal bleeding could fall from around 11% to 5% by delivering radiotherapy later in the day.View evidenceHide evidence

As statedurinary incontinence from 15% to 5%; rectal bleeding from around 11% to 5%

Why this verdict

The numerical estimates match the profile: for rs172933 heterozygotes, urinary incontinence risk was predicted to fall from 15% to 5% by avoiding treatment in the middle of the day; for rs696305 C/C, rectal bleeding risk was predicted to fall from 11% at 9:00 am to 5% at 5:00 pm. The story appropriately frames these as predictions/estimates rather than established clinical effects.

1

Study evidence

Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.

“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
2

Study evidence

Models including genotype, treatment timing, and their interaction predict that patients with PER3 rs696305 C/C (44% of cohort) would reduce predicted late rectal bleeding risk from 11% (treatment at 9:00 am) to 5% (treatment at 5:00 pm).11% → 5% absolute risk for RB

“Least absolute shrinkage and selection operator (LASSO) and logistic regression models incorporated genotypes of single-nucleotide polymorphisms in circadian rhythm genes, time of radiotherapy, and their interaction.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: observational associations and model-predicted differences do not establish causality.

    The story mentions validation and clinical trials, but it does not explicitly say the underlying study was observational or that the reported genotype/time relationships cannot establish causality.

    From Prospective observational cohort analysis (complete-case subset)

  • Specific subgroup details: rs696305 C/C represented 44% of patients for the rectal bleeding prediction, and rs172933 heterozygotes represented 36% for the urinary incontinence prediction.

    The story accurately reports the risk changes but only refers generally to 'some groups' or a 'particular PER3 genotype,' omitting the named variants and subgroup frequencies.

    From Prospective observational cohort analysis (complete-case subset); secondary_data

4 things the story did carry across
  • Core study design: multinational prospective observational REQUITE prostate cancer cohort, all receiving external beam radiotherapy, with 2-year follow-up; regression analyses used a complete-case subset of 877 from 1,760 patients.
  • Primary scientific finding: circadian genotypes, radiotherapy time-of-day, and genotype×time interactions were associated with late rectal bleeding and urinary incontinence.
  • Risk reductions are model-predicted absolute risks for genotype-defined subgroups, not observed effects from a randomized timing intervention.
  • Important limitation: the abstract profile does not report model performance metrics or external validation for the prediction models.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether radiotherapy time-of-day and circadian rhythm genotypes (especially PER3 variants) interact to affect late toxicity after external beam radiotherapy in prostate cancer (late rectal bleeding and urinary incontinence).Prospective observational cohort analysis (complete-case subset)Expand

In plain English

Prospective observational analysis of the multinational REQUITE prostate cancer cohort testing whether circadian SNP genotypes (including PER3 variants) interact with radiotherapy time-of-day to influence 2-year late toxicities (rectal bleeding and urinary incontinence). Regression models including LASSO variable selection and logistic regression found significant effects of genotype, treatment timing, and genotype×time interactions, with model-predicted reductions in absolute risk for specific PER3 genotypes when treated at certain times of day.

Key findings

  • Multivariable models showed significant effects of genotype, treatment timing, and genotype×time interaction for both late rectal bleeding and urinary incontinence.
  • For patients with PER3 rs696305 C/C (44% of cohort), model predictions indicate a reduction in late rectal bleeding risk from 11% when treated at 9:00 am to 5% when treated at 5:00 pm.absolute risk reduction 6 percentage points (11% → 5%)
“The analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.”
What this piece can’t prove
  • Analyses reported are from a complete-case subset (n=877) of the full cohort (n=1,760), which may affect generalizability and introduce selection bias.
  • Observational design: associations and model-predicted risk differences do not establish causality.
  • Abstract does not report measures of statistical uncertainty (e.g., confidence intervals, p-values) for the reported predicted risk changes.
2secondary dataDevelop and internally fit multivariable prediction models incorporating genotype, radiotherapy fraction timing, and genotype×time interaction (feature selection via LASSO; effect estimation via logistic regression) for late rectal bleeding and urinary incontinence in the REQUITE cohort.secondary dataExpand

In plain English

In the REQUITE prospective prostate cancer cohort the authors developed multivariable prediction models for two late radiotherapy toxicities (late rectal bleeding and urinary incontinence) using a complete-case subset (n=877). They applied LASSO for feature selection and fitted logistic regression models that included circadian SNP genotypes, time-of-day of radiotherapy fractions, and genotype×time interaction terms, and used the fitted models to generate absolute risk predictions for genotype-specific treatment-time scenarios (examples reported for PER3 SNPs rs696305 and rs172933).

Key findings

  • Models including genotype, treatment timing, and their interaction predict that patients with PER3 rs696305 C/C (44% of cohort) would reduce predicted late rectal bleeding risk from 11% (treatment at 9:00 am) to 5% (treatment at 5:00 pm).11% → 5% absolute risk for RB
  • For urinary incontinence, the fitted models predict a reduction in risk from 15% to 5% by avoiding treatment in the middle of the day for patients heterozygous for rs172933 (36% of cohort).15% → 5% absolute risk for UI
“Least absolute shrinkage and selection operator (LASSO) and logistic regression models incorporated genotypes of single-nucleotide polymorphisms in circadian rhythm genes, time of radiotherapy, and their interaction.”
What this piece can’t prove
  • Analysis reported in abstract used a complete-case subset (n=877) from the full cohort (n=1,760); abstract does not detail extent or pattern of missing data.
  • Abstract does not provide model performance metrics (discrimination, calibration), internal validation results, or external validation.
  • Abstract does not specify full model specification (covariates retained after LASSO), handling of potential confounders, or statistical significance levels for reported interactions.
3otherContextualize findings by comparison/consistency with prior breast cancer radiotherapy chronomodulation observations (interpretation rather than new primary data).narrative contextualization against prior literatureExpand

In plain English

The abstract states that the prostate cancer radiotherapy findings (genotype × time interactions affecting late toxicity) are consistent with earlier observations in breast cancer radiotherapy, presenting this as interpretive contextualization rather than new breast-cancer data.

Key findings

  • The authors assert consistency between their prostate cancer genotype × time–of–radiotherapy toxicity results and earlier breast cancer radiotherapy observations of genotype-modulated chronotoxicity.
“These results agree with the earlier findings in patients with breast cancer who have undergone radiotherapy.”
What this piece can’t prove
  • The abstract offers a qualitative statement of agreement without describing the prior breast cancer evidence (no citations, effect estimates, or comparative analyses provided).
  • Because no new breast-cancer data are included, the comparison rests on the authors' interpretation rather than on reanalysis or formal evidence synthesis.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

SelectedOpen access

Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research · 2026 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

283 poster Dose-volume-time-impact on toxicity in interstitial temporary HDR-Ir-192-brachytherapy (BT) for prostate cancer

Radiotherapy and Oncology · 2004 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.